Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

A gut-derived compound called propionate may slow the progression of Alzheimer's disease by reducing inflammation and plaque ...

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...